{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-21-021481","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2021-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.441315+00:00","generated_at":"2026-06-28T13:41:10.868851+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corcept Q3 revenue $96.1M (+11% YoY); narrows 2021 guide to $365-375M","bullets":["GAAP diluted EPS $0.24 vs $0.17 YoY; non-GAAP diluted EPS $0.30 vs $0.24.","Cash and investments $495.2M, up from $471.6M at June 30; repurchased 1.2M shares in Q3.","Plans Phase 3 trial in recurrent platinum-resistant ovarian cancer in Q1 2022; updated OS data expected Q1 2022.","Phase 2 NASH data to be presented at AASLD Nov 12-15; Phase 1b dose-finding trial initiated.","Relacorilant NDA submission for Cushing's syndrome expected Q2 2023; GRACE and GRADIENT trials enrolling."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-21-021481","json":"https://secwatch.observer/filing/0001628280-21-021481.json","markdown":"https://secwatch.observer/filing/0001628280-21-021481.md","text":"https://secwatch.observer/filing/0001628280-21-021481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000162828021021481/0001628280-21-021481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000162828021021481/cort-20211103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T13:41:10.868851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}